Bionime Corporation (TPE:4737)

Bionime Statistics

Total Valuation

Bionime has a market cap or net worth of TWD 4.51 billion. The enterprise value is 7.09 billion.

Market Cap	4.51B
Enterprise Value	7.09B

Important Dates

The next estimated earnings date is Friday, May 8, 2026.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

Bionime has 67.29 million shares outstanding. The number of shares has increased by 0.18% in one year.

Current Share Class	67.29M
Shares Outstanding	67.29M
Shares Change (YoY)	+0.18%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	8.63%
Owned by Institutions (%)	0.66%
Float	38.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.45
PB Ratio	2.57
P/TBV Ratio	4.08
P/FCF Ratio	13.31
P/OCF Ratio	9.11
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-39.34
EV / Sales	3.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	20.94

Financial Position

The company has a current ratio of 0.75, with a Debt / Equity ratio of 1.74.

Current Ratio	0.75
Quick Ratio	0.50
Debt / Equity	1.74
Debt / EBITDA	n/a
Debt / FCF	9.03
Interest Coverage	-3.04

Financial Efficiency

Return on equity (ROE) is -9.84% and return on invested capital (ROIC) is -4.50%.

Return on Equity (ROE)	-9.84%
Return on Assets (ROA)	-2.15%
Return on Invested Capital (ROIC)	-4.50%
Return on Capital Employed (ROCE)	-5.44%
Weighted Average Cost of Capital (WACC)	3.15%
Revenue Per Employee	3.68M
Profits Per Employee	-360,554
Employee Count	500
Asset Turnover	0.32
Inventory Turnover	2.36

Taxes

Income Tax	-70.09M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.64% in the last 52 weeks. The beta is -0.02, so Bionime's price volatility has been lower than the market average.

Beta (5Y)	-0.02
52-Week Price Change	+25.64%
50-Day Moving Average	60.81
200-Day Moving Average	62.62
Relative Strength Index (RSI)	44.02
Average Volume (20 Days)	255,130

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bionime had revenue of TWD 1.84 billion and -180.28 million in losses. Loss per share was -2.68.

Revenue	1.84B
Gross Profit	627.81M
Operating Income	-197.36M
Pretax Income	-249.41M
Net Income	-180.28M
EBITDA	-41.96M
EBIT	-197.36M
Loss Per Share	-2.68

Balance Sheet

The company has 484.81 million in cash and 3.06 billion in debt, with a net cash position of -2.57 billion or -38.25 per share.

Cash & Cash Equivalents	484.81M
Total Debt	3.06B
Net Cash	-2.57B
Net Cash Per Share	-38.25
Equity (Book Value)	1.76B
Book Value Per Share	25.95
Working Capital	-517.19M

Cash Flow

In the last 12 months, operating cash flow was 494.80 million and capital expenditures -156.18 million, giving a free cash flow of 338.62 million.

Operating Cash Flow	494.80M
Capital Expenditures	-156.18M
Depreciation & Amortization	155.40M
Net Borrowing	-115.68M
Free Cash Flow	338.62M
FCF Per Share	5.03

Margins

Gross margin is 34.15%, with operating and profit margins of -10.73% and -9.81%.

Gross Margin	34.15%
Operating Margin	-10.73%
Pretax Margin	-13.57%
Profit Margin	-9.81%
EBITDA Margin	-2.28%
EBIT Margin	-10.73%
FCF Margin	18.42%

Dividends & Yields

Bionime does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.18%
Shareholder Yield	-0.18%
Earnings Yield	-4.00%
FCF Yield	7.51%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 8, 2025. It was a forward split with a ratio of 1.0998680158.

Last Split Date	Sep 8, 2025
Split Type	Forward
Split Ratio	1.0998680158

Scores

Bionime has an Altman Z-Score of 0.69 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.69
Piotroski F-Score	2